{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:45:52Z","timestamp":1789544752986,"version":"build-2803163510"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12288-020-01294-9","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T06:18:18Z","timestamp":1591683498000},"page":"169-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Efficacy of Bendamustine-Rituximab in Treatment Na\u00efve Symptomatic Follicular Lymphoma: An Institutional Analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Ajay","family":"Gogia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"1294_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","volume":"15","author":"NH Fowler","year":"2014","unstructured":"Fowler NH, Davis RE, Rawal S et al (2014) Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15:1311\u20131318","journal-title":"Lancet Oncol"},{"key":"1294_CR2","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944\u20132952","journal-title":"Blood"},{"key":"1294_CR3","first-page":"681","volume":"18","author":"A Gogia","year":"2017","unstructured":"Gogia A, Raina V, Kumar L et al (2017) Follicular lymphoma: an Institutional analysis. Asian Pac J Cancer Prev. 18:681\u2013685","journal-title":"Asian Pac J Cancer Prev."},{"key":"1294_CR4","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label multicentre, randomized, phase 3 noninferiority trial. Lancet 381:1203\u20131210","journal-title":"Lancet"},{"key":"1294_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","volume":"23","author":"P Mondello","year":"2018","unstructured":"Mondello P, Steiner N, Willenbacher W et al (2018) Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicentre, retrospective study. Oncologist 23:454\u2013460","journal-title":"Oncologist"},{"key":"1294_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P et al (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 379:934\u2013947","journal-title":"N Engl J Med"},{"issue":"7","key":"1294_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D385N6C9JF","volume":"16","author":"HS Alamdari","year":"2010","unstructured":"Alamdari HS, Pinter-Brown L, Cassarino DS, Chiu MW (2010) Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J 16(7):1","journal-title":"Dermatol Online J"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-020-01294-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-020-01294-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-020-01294-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T07:16:15Z","timestamp":1666854975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-020-01294-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1294"],"URL":"https:\/\/doi.org\/10.1007\/s12288-020-01294-9","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"12 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"There is no conflict of interests for all 5 authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study is in compliance with ethical standards. Institute ethical clearance was obtained for the retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}